Evidence map›Paper›PMID 38785181›Full record

ArticleCancer medicine2024

The impact of the route to diagnosis in nephroblastoma.

Marvin Mergen, Nils Welter, Rhoikos Furtwängler, Patrick Melchior, Christian Vokuhl, Manfred Gessler, Clemens-Magnus Meier, Leo Kager, Jens-Peter Schenk, Norbert Graf

Abstract read
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Marvin MergenDepartment of Pediatric Oncology and Hematology, Saarland University Medical Center, Homburg, Germany.ORCID 0000-0002-3891-580X
Nils WelterDepartment of Pediatric Oncology and Hematology, Saarland University Medical Center, Homburg, Germany.ORCID 0000-0001-9874-4726
Rhoikos FurtwänglerDivison of Paediatric Hematology and Oncology, Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.ORCID 0000-0002-1967-8343
Patrick MelchiorDepartment of Radiation Oncology, Saarland University Medical Center, Homburg, Germany.ORCID 0000-0003-2305-8857
Christian VokuhlSection of Pediatric Pathology, Department of Pathology, University Hospital Bonn, Bonn, Germany.ORCID 0000-0002-4138-4536
Manfred GesslerDevelopmental Biochemistry and Comprehensive Cancer Center Mainfranken, Theodor-Boveri-Institute/Biocenter, University of Würzburg, Würzburg, Germany.ORCID 0000-0002-7915-6045
Clemens-Magnus MeierDepartment of General Surgery, Visceral, Vascular and Pediatric Surgery, Saarland University Medical Center, Homburg, Germany.ORCID 0000-0001-5553-6302
Leo KagerDepartment of Pediatrics, St. Anna Children's Hospital, Medical University Vienna, Vienna, Austria.ORCID 0000-0003-4954-6488
Jens-Peter SchenkDepartment of Diagnostic and Interventional Radiology, Division of Pediatric Radiology, University Hospital Heidelberg, Heidelberg, Germany.ORCID 0000-0002-0588-0225
Norbert GrafDepartment of Pediatric Oncology and Hematology, Saarland University Medical Center, Homburg, Germany.ORCID 0000-0002-2248-323X

Funding

Deutsche Krebshilfe 50-2709-GR2Deutsche Krebshilfe 70-1899Elterninitiative krebskranker Kinder im Saarland e.V
6 · The paper itself

Abstract

introductionWilms tumor (WT) is the most common childhood kidney cancer. It is a rapid growing embryonal tumor in young children and can be diagnosed with and without tumor related symptoms.

methodsWe retrospectively analyzed the route to diagnosis of WT treated prospectively according to the SIOP 93-01/GPOH and 2001/GPOH in Germany between 1993 and 2022. Four routes were defined: diagnosis due to tumor-related symptoms, incidental diagnosis during another disease, diagnosis by preventive examinations, and diagnosis within a surveillance program. For these groups we compared clinical and tumor characteristics and outcome.

resultsOf 2549 patients with WT 1822 (71.5%) were diagnosed by tumor-related symptoms, 472 (18.5%) incidentally, 213 (8.4%) by preventive medical examinations, and 42 (1.6%) by surveillance. Age, general health status, tumor volume, and local and overall stage varied significantly between these groups. The youngest patients were those diagnosed by preventive medical examination (mean: 1.70 years). These patients also showed the best general health status. Tumor volume at diagnosis (549 mL) and after preoperative chemotherapy (255 mL) was significantly higher for children with tumor-related symptoms. The highest percentage of local stage I (78.6%) and the lowest percentage of metastatic disease (4.8%) was found in the surveillance group. The outcome of patients was not significantly different, with up to 19.0% relapses in the surveillance group and 3.0% deaths in the group with tumor-related symptoms.

conclusionThe route to diagnosis of WT correlates with age, general health status, tumor volume, and stage distribution, but does not impact the outcome of patients. Nonetheless, diagnosis without tumor related symptoms results in lower treatment burden and thus improved quality of life.

Indexed as

Kidney NeoplasmsWilms TumorAdolescentChildChild, PreschoolFemaleGermanyHumansInfantMaleNeoplasm StagingRetrospective StudiesTumor Burdennephroblastomaoutcomepatient and tumor characteristicsroute to diagnosis

Identifiers

PMID38785181
PMCPMC11117195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.